Literature DB >> 7677084

Implications for cost-effectiveness. Combination therapy for systemic hypertension.

N M Kaplan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7677084     DOI： 10.1016/s0002-9149(99)80162-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  7 in total

Review 1.  Pharmacoeconomics of hypertension management: the place of combination therapy.

Authors:  E Ambrosioni
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 2.  Drug interactions with irbesartan.

Authors:  M R Marino; N N Vachharajani
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 3.  Angiotensin converting enzyme inhibitors: are they preferred first-line therapy?

Authors:  S P Glasser
Journal:  Curr Hypertens Rep       Date:  2000-08       Impact factor: 5.369

4.  Low-dose combination therapy as first-line hypertension treatment for blacks and nonblacks.

Authors:  L M Prisant; J M Neutel; K Ferdinand; V Papademetriou; V DeQuattro; W D Hall; M R Weir
Journal:  J Natl Med Assoc       Date:  1999-01       Impact factor: 1.798

Review 5.  Fixed combination verapamil SR/trandolapril.

Authors:  M Dooley; K L Goa
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

6.  Effects of verapamil slow release plus trandolapril combination therapy on essential hypertension.

Authors:  Ulver Derici; Sukru Sindel; Turgay Arinsoy; Musa Bali; Berna Goker; Mustafa Cemri; Enver Hasanoglu
Journal:  Curr Ther Res Clin Exp       Date:  2003-01

Review 7.  Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials.

Authors:  Gianpaolo Reboldi; Giorgio Gentile; Fabio Angeli; Paolo Verdecchia
Journal:  Vasc Health Risk Manag       Date:  2009
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.